Rizk, Dana

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12

Individualised treatment effects of corticosteroids in IgA nephropathy

Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 2